Telpoeptide: A dual-target breakthrough, reshaping the treatment landscape for diabetes and obesity.

2022 was undoubtedly a landmark year in the treatment of chronic metabolic diseases. A new drug called Zepbound® (trade name: Mounjaro®) emerged, stunning the medical community with its remarkable efficacy data. It not only brought new hope to patients with type 2 diabetes, but also officially ushered in a new era of drug treatment for obesity.

I. What is telpoeptide?

Telpoeptide is a novel, once-weekly subcutaneous injection dual agonist of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Simply put, it mimics the function of two important intestinal hormones (“incretins”) in the body—GIP and GLP-1—to regulate blood sugar and weight through a “two-pronged” mechanism.

II. Revolutionary "Dual-Target" Mechanism of Action

Compared to traditional single GLP-1 receptor agonists (such as smegglutinin), telpolide's dual mechanism of action gives it a more powerful overall efficacy:

1. Blood sugar control:
• Promotes insulin secretion: When blood sugar rises, it significantly stimulates pancreatic β cells to secrete insulin, precisely lowering blood sugar with a very low risk of hypoglycemia.
• Inhibits glucagon: Reduces the secretion of glucagon (a glucose-raising hormone) by pancreatic α cells, thereby inhibiting hepatic glycogen output.
• Delays gastric emptying: Slows down the rate at which food moves from the stomach into the small intestine, reducing postprandial blood glucose spikes.
2. Weight Management:
• Central appetite suppression: It acts directly on the appetite regulation center in the hypothalamus of the brain, producing a strong feeling of fullness and reducing hunger, which is the core of its weight loss effect.
• Increased energy expenditure: Studies have shown that GIP receptor activation may help increase energy expenditure in adipose tissue.

This synergistic effect allows telpolide to exhibit a remarkable "1+1>2" effect in lowering blood sugar and reducing weight.

III. Impressive Clinical Data: The SURPASS and SURMOUNT Series Studies

The efficacy of telpolide has been fully validated through a series of large-scale phase III clinical trials (SURPASS series for diabetes, SURMOUNT series for obesity):

• • For type 2 diabetes (SURPASS study):
  
• • In monotherapy or combination therapy, its glucose-lowering effect (the extent of reduction in glycated hemoglobin HbA1c) is superior to all control drugs, including potent basal insulin and existing GLP-1 receptor agonists.
   
• • Patients experienced significant weight loss, with an average weight loss of 6-12 kg (depending on the dosage), achieving the ideal goal of "lowering blood sugar and losing weight".
  
• • For obesity or overweight (SURMOUNT study):
   
• • At 72 weeks, patients in the highest dose (15mg) group experienced an average weight loss of 20.9%. This figure surpasses all previous anti-obesity drugs and is comparable to the effects of metabolic surgery.
  
• • It also performs well in improving cardiovascular metabolic risk factors such as blood pressure, blood lipids, and inflammatory markers.

IV. Significance and Breakthrough: More Than Just Numbers

1. Upgraded Treatment Philosophy: The success of telpolide marks a fundamental shift in the treatment of metabolic diseases from "simply controlling blood sugar" to "comprehensive management of metabolic health." Weight management has become one of the core goals of treatment.
2. A leap forward in drug efficacy: It has elevated the effectiveness of drug treatment for obesity to an unprecedented level, providing an extremely effective option for countless severely obese patients who are unwilling or unable to undergo surgery.
3. Expectations of cardiovascular benefits: Based on its strong metabolic improvement effects, the academic community generally expects that telpolide will bring clear cardiovascular benefit (related studies are ongoing), and may further reduce the risk of myocardial infarction, stroke and other diseases.

V. Challenges and Prospects

Despite its promising prospects, the application of telpolide still faces challenges:

Side effects: Common side effects are similar to those of GLP-1 drugs, including gastrointestinal reactions such as nausea, vomiting, diarrhea, and constipation, which usually lessen with prolonged treatment. It is necessary to start with a low dose and titrate slowly.
• Accessibility and cost: Currently, it is expensive and not covered by health insurance in many areas. The economic burden of long-term treatment is an important consideration.
• Long-term data: Longer-term real-world data are needed to confirm its durable efficacy and rare adverse reactions.

Looking ahead, the emergence of telpolide is just the beginning. Its success has validated the enormous potential of a multi-target strategy in the treatment of metabolic diseases. Currently, research is moving towards three-target and even multi-target agonists. Furthermore, the development of oral formulations is underway, which is expected to further improve patient convenience and adherence.

Conclusion

Telpoeptide is more than just a new drug; it's a therapeutic revolution. It redefines the upper limit of our understanding of the efficacy of drug treatments for diabetes and obesity with solid clinical data. As research deepens and its application becomes more widespread, it is expected to benefit hundreds of millions of patients worldwide, profoundly changing the landscape of metabolic disease prevention and treatment, and leading us into a new era of healthier and more controllable metabolic health management.